Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Worldwide Polymerase Chain Reaction Industry to 2027 – Growing Demand for Point of Care Testing Presents Opportunities

Published

on

Dublin, Aug. 19, 2021 (GLOBE NEWSWIRE) — The “Polymerase Chain Reaction (PCR) Global Market – Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

PCR is an enzymatic reaction process in which multiple copies of desired DNA sequence is obtained in a short period of time. The technique is broadly accepted in research and clinical diagnostic application due to its high accuracy and sensitivity. The evolution of PCR instruments with different designs such as interchangeable modules, dual & multiblock capacity, development of advanced Real-time PCR and digital PCR with multiplexing and analytical capabilities, development of various reagents & consumables and incorporation of microfluidic and other advanced technologies for the development of portable PCR will further advance the PCR applications in clinical diagnostic and industrial applications.

The Polymerase Chain Reaction (PCR) global market is estimated to be $21,408.8 million in 2020. The factors driving the market are raising the incidence of infectious and non-infectious diseases, increase in demand for early disease detection, diagnosis & treatment, growing focus towards the development of personalized medicine, increasing advancements in PCR technologies and increasing demand for point of care testing. However, lack of skilled personnel to use advanced PCR Instruments and data analysis software, high cost of advanced instruments, presence of alternative molecular and immunology techniques, and stringent government regulations are expected to hamper the market growth.

The PCR market is classified into products, application, end-user and geography. The PCR products global market is segmented into instruments, reagents & consumables and software & services. Among the products, the Reagents & consumables segment accounted for the largest revenue in 2020 due to an increase in demand for reagents & consumables for research and diagnostic applications. Reagents and consumables are sub-segmented into enzymes, dNTPs, template DNA, primers and probes, buffers, reagents kits or master mixes and assay kits, nuclease free water, consumable and others (dye and beads). Among these Reagents kits or master mixes and assay kits is accounted for the highest revenue in 2020 due to an increase in demand for assay kits in diagnostic applications particularly in COVID-19 diagnosis.

The enzymes are fastest growing consumable segment at a high single digit CAGR from 2020 to 2027. The PCR instruments global market is sub-segmented into Standard PCR, Real-Time PCR and Digital PCR. Among the instruments, Real-Time PCR is accounted for the highest revenue in 2020 due to increased utilization of real-time PCR instruments in diagnostic applications particularly in COVID-19 diagnosis and research applications. The digital PCR is fastest growing instruments segment at a mid teen CAGR from 2020 to 2027.

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Key Takeaways
2.2 Scope of the Report
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology
2.6.1 Market Size Estimation
2.6.2 Market Breakdown and Data Triangulation
2.6.3 Secondary Sources
2.6.4 Key Data Points from Secondary Sources
2.6.5 Primary Sources
2.6.6 Key Data Points from Primary Sources
2.6.7 Assumptions

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers and Opportunities
3.3.1.1 Rising Incidence of Infectious and Non-Infectious Diseases and Demand for Early Detection, Diagnosis & Treatment
3.3.1.2 Increasing Focus Towards the Development of Personalized Medicines
3.3.1.3 Growing Demand for Point of Care Testing
3.3.1.4 Increasing Demand for Prenatal Testing
3.3.2 Restraints and Threats
3.3.2.1 Lack of Skilled Personnel to Use Advanced Instruments
3.3.2.2 High Cost of Advanced PCR System
3.3.2.3 Development of Alternate Technologies
3.3.2.4 Stringent Regulatory Framework Limits Advancements in the PCR Market
3.4 Regulatory Affairs
3.5 Porter’s Five Force Analysis
3.6 Supply Chain Analysis
3.7 Funding Scenario
3.8 Patent Analysis
3.9 Technological Advancements
3.9.1 Introduction
3.9.2 Crystal Digital PCR Technology
3.9.3 Real Time Remote Monitoring
3.9.4 Artificial Intelligence in PCR
3.9.5 Infrared Mediated Non-Contact Thermocycling
3.9.6 Nano-PCR
3.10 Impact of Covid-19 on PCR Market
3.11 Market Share Analysis by Major Players
3.11.1 PCR Global Market Share Analysis
3.11.2 Standard PCR Global Market Share Analysis
3.11.3 Real Time PCR Global Market Share Analysis
3.11.4 Digital PCR Global Market Share Analysis

4 PCR Global Market, by Product
4.1 Introduction
4.2 Instruments
4.2.1 Standard PCR
4.2.2 Real Time PCR
4.2.3 Digital PCR
4.3 Reagents and Consumables
4.3.1 Enzymes
4.3.2 Deoxynucleotide Triphosphate’s (Dntp’s)
4.3.3 Templates or Controls
4.3.4 Primers and Probes
4.3.5 Buffers
4.3.6 Reagent Kits or Master Mixes and Assay Kits
4.3.7 Nuclease Free Water
4.3.8 Consumables
4.3.9 Other Reagents and Consumables
4.4 Software & Services

5 PCR Global Market, by Application
5.1 Introduction
5.2 Clinical Diagnostics
5.2.1 Infectious Diseases
5.2.1.1 Hepatitis B and C Testing
5.2.1.2 Tuberculosis Diagnosis
5.2.1.3 Hiv Diagnosis
5.2.1.4 Covid-19 Diagnosis
5.2.1.5 Others
5.2.2 Non-Infectious Diseases
5.2.2.1 Cancer
5.2.2.2 Genetic Testing
5.2.2.3 Others
5.3 Industrial Applications
5.3.1 Agriculture
5.3.2 Environment
5.3.3 Applied Testing
5.3.3.1 Forensics
5.3.3.2 Food Safety Testing
5.3.4 Animal Husbandry
5.3.5 Biomedical Research
5.3.5.1 Dna Sequencing
5.3.5.2 Genotyping
5.3.5.3 Gene Expression Analysis
5.3.5.4 Dna Cloning
5.3.5.5 Others
5.3.6 Other PCR Industry Applications
5.4 Other PCR Applications

6 PCR Global Market, by End-Users
6.1 Introduction
6.2 Hospitals and Laboratories
6.3 Pharmaceuticals, Cro’s and Biotech
6.4 Academics and Research Institutions
6.5 Others

7 Regional Analysis
7.1 Introduction
7.2 North America
7.2.1 U.S.
7.2.2 Rest of North America
7.3 Europe
7.3.1 Germany
7.3.2 U.K.
7.3.3 France
7.3.4 Rest of Europe
7.4 Asia-Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Rest of Apac
7.5 RoW
7.5.1 Brazil
7.5.2 Rest of Latin America
7.5.3 Middle East & Africa

8 Competitive Landscape
8.1 Introduction
8.2 Approvals
8.3 New Product Launch
8.4 Collaborations and Partnerships
8.5 Acquisitions
8.6 Others

9 Major Companies
9.1 Abbott Laboratories, Inc.
9.1.1 Overview
9.1.2 Financials
9.1.3 Product Portfolio
9.1.4 Key Developments
9.1.5 Business Strategy
9.1.6 SWOT Analysis
9.2 Becton Dickinson and Company
9.2.1 Overview
9.2.2 Financials
9.2.3 Product Portfolio
9.2.4 Key Developments
9.2.5 Business Strategy
9.2.6 SWOT Analysis
9.3 Biomerieux Sa
9.3.1 Overview
9.3.2 Financials
9.3.3 Product Portfolio
9.3.4 Key Developmensts
9.3.5 Business Strategy
9.3.6 SWOT Analysis
9.4 Bio-Rad Laboratories
9.4.1 Overview
9.4.2 Financials
9.4.3 Product Portfolio
9.4.4 Key Developments
9.4.5 Business Strategy
9.4.6 SWOT Analysis
9.5 Danaher Corporation
9.5.1 Overview
9.5.2 Financials
9.5.3 Product Portfolio
9.5.4 Key Developments
9.5.5 Business Strategy
9.5.6 SWOT Analysis
9.6 Exact Sciences Corporation
9.6.1 Overview
9.6.2 Financials
9.6.3 Product Portfolio
9.6.4 Key Developments
9.6.5 Business Strategy
9.6.6 SWOT Analysis
9.7 F.Hoffmann-La Roche Ltd
9.7.1 Overview
9.7.2 Financials
9.7.3 Product Portfolio
9.7.4 Key Developments
9.7.5 Business Strategy
9.7.6 SWOT Analysis
9.8 Merck Kgaa
9.8.1 Overview
9.8.2 Financials
9.8.3 Product Portfolio
9.8.4 Key Developments
9.8.5 Business Strategy
9.8.6 SWOT Analysis
9.9 Perkinelmer, Inc.
9.9.1 Overview
9.9.2 Financials
9.9.3 Product Portfolio
9.9.4 Key Developments
9.9.5 Business Strategy
9.9.6 SWOT Analysis
9.10 Qiagen N.V.
9.10.1 Overview
9.10.2 Financials
9.10.3 Product Portfolio
9.10.4 Key Developments
9.10.5 Business Strategy
9.10.6 SWOT Analysis
9.11 Thermo Fisher Scientific, Inc.
9.11.1 Overview
9.11.2 Financials
9.11.3 Product Portfolio
9.11.4 Key Developments
9.11.5 Business Strategy
9.11.6 SWOT Analysis

Companies Mentioned

  • B BlackBio Biotech India Limited
  • 3CR Bioscience
  • Abbott Laboratories, Inc.
  • ACTGene, Inc.
  • ADS Biotec, Inc.
  • Agilent Technologies
  • Ahram Biosystems, Inc.
  • Altona Diagnostics GmbH
  • Amoy Diagnostics
  • Ampliqon A/S
  • Analytik Jena AG
  • Anatolia Geneworks
  • Andiatec GmbH
  • AniCon Labor GmbH
  • Anitoa Systems, LLC
  • Atila Bio Systems Inc
  • Becton Dickinson and Company
  • BforCure
  • BGI Group
  • Binx Health Inc.
  • Bio Basic Inc.
  • BioCheck, Inc.
  • Biofidelity
  • BioinGentech ,
  • BIOLABMIX LLC
  • Biomeme, Inc
  • Biomerieux SA
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bioron GmbH
  • Biosynex S.A.
  • Biotecon Diagnostics GmbH
  • Biotype Diagnostic GmbH
  • Blue-Ray Biotech
  • Brooks Life Sciences
  • Bruker
  • CareDx, Inc.
  • Carpegen GmbH
  • Chai Inc.
  • Cleaver Scientific Ltd.
  • CLONIT Srl.
  • Co-Diagnostics
  • Combinati INC
  • Convergent-technologies
  • Corning, Inc.
  • CyberGene AB
  • Da An Gene Co.
  • Danaher Corporation
  • Devyser AB
  • DiaCarta, Inc.
  • DiaSorin S.p.A.
  • Dropworks, Inc.
  • Entopsis, Inc.
  • EntroGen
  • Eppendorf, AG
  • Eurofins Scientific S.E.
  • Exact sciences
  • F.Hoffmann-La Roche AG
  • Fluidigm corporation
  • Genedrive plc
  • GeneFirst Ltd.
  • Genekam Biotechnology AG
  • GeneProof A.S.
  • Genesystem.co.kr
  • Genome Diagnostics B.V.
  • Genome Diagnostics Pvt Ltd.
  • Genomed
  • Genomictree Inc.
  • GNA Biosolutions GmbH
  • Hangzhou LongGene Scientific Instruments Co.,Ltd
  • Hologics
  • Hy Laboratories Ltd.
  • Hygiena, LLC
  • INTAS Science Imaging Instruments GmbH
  • Invivoscribe, Inc
  • Jena Bioscience GmbH
  • JN Medsys
  • Kaneka Eurogentec S.A.
  • Kogene.co.kr
  • KOMA Biotech, Inc.
  • Kyratec
  • LABGENE Scientific SA
  • Macrogen Inc.
  • Menarini Diagnostics
  • Merck KgaA
  • Meridian Bioscience
  • MicroGEM
  • Minerva Biolabs GmbH
  • miniPCR bio
  • Minute Molecular Diagnostics
  • Molbio Diagnostics Pvt. Ltd.
  • Molzym GmbH & Co. KG
  • Mylab Discovery Solutions
  • Nimagen B.V.
  • Norgen Biotech Corp.
  • Novacyt
  • Nuclein, LLC.
  • Ocimum Biosolutions, Ltd
  • Pathofinder B.V.
  • PCR Biosystems Ltd
  • PCR Max Ltd.
  • PentaBase ApS
  • Perkin Elmer
  • Precipio, Inc.
  • Premier Biosoft International
  • Promega Corporation
  • Qiagen N.V.
  • Qualiplante SAS
  • QuantuMDx
  • Quidel Corporation
  • Reagecon Diagnostics Ltd.
  • Scope Fluidics
  • Seegene, Inc.
  • Siemens Healthcare GmbH
  • Sinaclon
  • SolGent co, LTD
  • SpeeDx
  • Star Array company
  • Stilla Technologies
  • Takara Bio Inc.
  • Tetracore, Inc.
  • Thermo Fisher Scientific, Inc.
  • Ubiquitome
  • Vircell S.L.
  • Visby Medical
  • Zhengzhou Nanbei Instrument Equipment Co. Ltd.
  • Zymo Research Corporation

For more information about this report visit https://www.researchandmarkets.com/r/oyqxhc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

THE 2024 GLOBAL EXPLORATION SUMMIT IS ANNOUNCED AT THE 120th EXPLORERS CLUB ANNUAL GALA IN NEW YORK

Published

on

the-2024-global-exploration-summit-is-announced-at-the-120th-explorers-club-annual-gala-in-new-york

Porto and Terceira Island to Host the ‘Davos of Exploration’ – The GLEX Summit
NEW YORK, April 24, 2024 /PRNewswire/ — The Explorers Club and Expanding World, are thrilled to announce the fifth edition of The GLEX Summit, known as the ‘Davos of Exploration,’ set to take place from June 15 to 19 on Porto city and Terceira Island in the Azores, Portugal.

This year, Porto will Ignite the summit, followed by two days of discussions and exploration in the historic city of Angra do Heroísmo on Terceira Island. From the depths of the oceans to new space missions, the power and future of exploration will be explored in these two World Heritage cities, deeply connected to the history of exploration.
The 2024 GLEX Summit will revolve around the latest discoveries and groundbreaking missions shaping the future of our planet. Highlights of the summit include the Artemis mission, which plans to send astronauts back to the moon for the first time since 1972, and the role of Space and the Oceans in researching and mitigating the effects of climate change. Notable sessions will also delve into the unfortunate incident of the submersible implosion that took place on Titan and the recording of an episode of the BBC’s acclaimed science comedy show ‘The Infinite Monkey Cage,’ hosted by physicist Brian Cox and comedian Robin Ince.
This prestigious event will bring together over three dozen explorer and scientist legends from around the world. Confirmed physicist and researcher Brian Cox, NASA Chief Scientist James Garvin, Aquanaut Fabien Cousteau, Oceanographer David Gallo, Cosmonaut Mike Massimino, Nasa ISS CapCom Tess Caswell, among many others global Explorers and Scientists.
For further inquiries about The GLEX Summit and press accreditation, please contact:
Marco Barbosa [email protected], +351917345744
Photo: https://mma.prnewswire.com/media/2395857/GLEX_Summit.jpg
 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/the-2024-global-exploration-summit-is-announced-at-the-120th-explorers-club-annual-gala-in-new-york-302125563.html

Continue Reading

Artificial Intelligence

Hillstone Networks is Named in Microsegmentation Solutions Landscape Report

Published

on

hillstone-networks-is-named-in-microsegmentation-solutions-landscape-report

Hillstone Networks delivers advanced Microsegmentation across different verticals.. 
SANTA CLARA, Calif., April 24, 2024 /PRNewswire/ — Hillstone Networks, a leading provider of cybersecurity solutions, has been included in the Forrester Microsegmentation Solutions Landscape, Q2 2024 report. The report offers an overview of the Microsegmentation market, focused on the vendors who deliver solutions for protection of critical resources, combating ransomware, and contributing to compliance adherence. The report provides security professionals a snapshot of these named vendors, considering factors such as size, geographic focus, and use cases to select the most suitable option for their targeted use cases or needs. 

In the Landscape Report, Forrester states that “Zero Trust is all about replacing bodies of implicit trust with explicit policy. In physical and virtual networks, the application of this principle is referred to as microsegmentation…. [It] was one of the first true Zero Trust technologies developed after Forrester published the initial Zero Trust reports.”  
Forrester states in the report that the main trend is “organizations are finally getting serious about Zero Trust. Some, proactively, are implementing microsegmentation as part of a Zero Trust strategy or initiative. Others are implementing it because they got hit by ransomware and are trying to avoid it again. But all of them are doing Zero Trust with microsegmentation.”
“Being recognized as a vendor in the Microsegmentation solution landscape underscores for us the pivotal role our technology plays in safeguarding critical assets and thwarting ransomware threats. We believe it reaffirms our commitment to providing cutting-edge security measures built on an innovative and AI-powered platform that help our customers defend against evolving cyber risks, ensuring resilience and trust,” states Tim Liu, CTO and Co-founder at Hillstone Networks.
Hillstone’s Microsegmentation solution provides the following key benefits:
Advanced and extensive Microsegmentation for physical servers, virtual machines, cloud hosts, and containers, seamlessly compatible with multiple platforms.Comprehensive, integrated Layer 4 to 7 security and malware features (Next Generation Firewall, Intrusion Prevention System, AntiVirus, URL filtering, DDoS, and bot defense), and complete vulnerability management across the entire application lifecycle.Distributed architecture for easy scaling and portability.Centralized and comprehensive visibility to reduce gaps in the threat surface.Learn more about Hillstone Networks solutions here.
About Hillstone Networks
Hillstone Networks’ Integrative Cybersecurity approach is based on a visionary, AI-powered, and accessible platform, delivering coverage, control, and consolidation to secure over 28,000 global enterprises.
Media ContactZeyao Hu+1 [email protected]
Logo – https://mma.prnewswire.com/media/765968/Hillstone_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/hillstone-networks-is-named-in-microsegmentation-solutions-landscape-report-302125530.html

Continue Reading

Artificial Intelligence

Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System

Published

on

tetra-pharm-technologies-and-glysious-announce-collaboration-to-develop-transdermal-combination-drugs-targeting-the-endocannabinoid-system

The collaboration brings together Tetra Pharm Technologies’ expertise in enabling technology with Glysious’ proprietary transdermal drug delivery system, renowned for its effectiveness, comfort, and convenience.
COPENHAGEN, Denmark, April 24, 2024 /PRNewswire/ — Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies’ pipeline candidates. The joint invention aims to revolutionize transdermal release of “difficult-to-formulate” compounds targeting the endocannabinoid system.

Tetra Pharm Technologies has focused intensively on formulation expertise, that is, how the molecules are effectively integrated with a drug delivery system to reach their desired targets. Glysious has worked rigorously on the development of an adhesive patch for transdermal drug delivery since the company’s incorporation in 2020.
“The Glysious technology enables precision, sustained dosing, and allows for a high drug load and effective emptying of patches. The transdermal patches remain in place and are very comfortable and convenient to use, resulting in improved patient compliance. However, we have identified challenges with standard formulation strategies, not providing acceptable drug release due to shortcomings of the formulation matrix”, says Professor, Dr.Techn. Anne Ladegaard Skov, Chief Scientific Officer, Glysious.
Back in 2023 Glysious and Tetra Pharm Technologies performed early in-vitro feasibility tests, integrating Tetra Pharma Technologies’ proprietary enabling technology for delivery of poorly soluble compounds with Glysious’ patch.
Dr. Morten Allesø, Chief Scientific Officer, Tetra Pharm Technologies, adds: “Although both parties were aware of the uniqueness of our respective technologies, we were positively surprised to find a five-fold increase in performance of our combination product compared to conventional formulation technologies. This is truly remarkable, and we consider it our shared obligation to further advance this technology to the benefit of the patients.”
The objectives of the collaboration include conducting comprehensive in-vitro and in-vivo studies to evaluate the performance and efficacy of the combined drug delivery system. Additionally, Tetra Pharm Technologies and Glysious plan to pursue a common patent for the joint invention, ensuring that their innovative technology remains protected and exclusive.
“We are excited to collaborate with the innovative team in Tetra Pharm Technologies on this transdermal drug delivery system paving the way for commercialization and scaling of the Glysious technology within the pharma segment”, says Stina Bjerg Nielsen, Chief Executive Officer, Glysious.
Martin Rose, Chief Executive Officer, Tetra Pharm Technologies, concludes: “The collaboration represents a unique opportunity to harness the synergies between our respective technologies. By combining our expertise, we aim to develop a transdermal drug delivery system that offers superior efficacy, convenience, and patient compliance, supporting several of our pipeline programs”.
As part of the collaboration, the partners will exchange expertise, knowledge, and resources. In addition, Tetra Pharm Technologies and Glysious will conduct joint research, experiments, and tests as required for the development of a joint patent. The scope of the collaboration is focused on disease indications such as pain, sleep disorders, and appetite regulation.
About Tetra Pharm Technologies
Tetra Pharm Technologies is a Danish biopharmaceutical company established in 2018 with a vision to be a leader in research and development of pharmaceutical drugs for the treatment of diseases related to the endocannabinoid system. For more information, please visit www.tetrapharm.eu
About Glysious
Glysious is a Danish medtech company, incorporated in 2020, that develops patches, creams, spray, and foams with controlled release of active ingredients for cosmetics and life science applications. For more information, please visit www.glysious.com
For further informationJacob SchlundtChief Marketing OfficerTetra Pharm [email protected]+45 51976225
Stina Bjerg NielsenChief Executive [email protected]+45 3053 5393
Photo – https://mma.prnewswire.com/media/2393210/Tetra_Pharm_Technologies_Deal.jpgLogo – https://mma.prnewswire.com/media/1988863/Tetra_Pharm_Technologies_Logo.jpg
 
 
 

View original content:https://www.prnewswire.co.uk/news-releases/tetra-pharm-technologies-and-glysious-announce-collaboration-to-develop-transdermal-combination-drugs-targeting-the-endocannabinoid-system-302123136.html

Continue Reading

Trending